Cozzolino M et al. |
Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study. |
2014 |
Nephrol. Dial. Transplant. |
pmid:24500308
|
Sahin I et al. |
Paricalcitol counteracts the increased contrast induced nephropathy caused by renin-angiotensin-aldosterone system blockade therapy in a rat model. |
2014 |
Eur Rev Med Pharmacol Sci |
pmid:25339484
|
Ritter C et al. |
Cardiac and renal effects of atrasentan in combination with enalapril and paricalcitol in uremic rats. |
2014 |
Kidney Blood Press. Res. |
pmid:25300759
|
González-Mateo GT et al. |
Paricalcitol reduces peritoneal fibrosis in mice through the activation of regulatory T cells and reduction in IL-17 production. |
2014 |
PLoS ONE |
pmid:25279459
|
Choudhury S et al. |
Abnormal calcium handling and exaggerated cardiac dysfunction in mice with defective vitamin d signaling. |
2014 |
PLoS ONE |
pmid:25268137
|
Zoccali C et al. |
Paricalcitol and endothelial function in chronic kidney disease trial. |
2014 |
Hypertension |
pmid:25259743
|
Hansen D et al. |
The influence of vitamin D analogs on calcification modulators, N-terminal pro-B-type natriuretic peptide and inflammatory markers in hemodialysis patients: a randomized crossover study. |
2014 |
BMC Nephrol |
pmid:25112372
|
Carpenter TO et al. |
Effect of paricalcitol on circulating parathyroid hormone in X-linked hypophosphatemia: a randomized, double-blind, placebo-controlled study. |
2014 |
J. Clin. Endocrinol. Metab. |
pmid:25029424
|
Coyne DW et al. |
A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD. |
2014 |
Clin J Am Soc Nephrol |
pmid:24970869
|
Gueutin V et al. |
[Diabetic nephropathy: emerging treatments]. |
2014 |
Nephrol. Ther. |
pmid:24938412
|